The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel.
about
NVP-LDE225, a potent and selective SMOOTHENED antagonist reduces melanoma growth in vitro and in vivoThe anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signalingCRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutationsThe Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin CancerPhase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancersA new 2α,5α,10β,14β-tetraacetoxy-4(20),11-taxadiene (SIA) derivative overcomes paclitaxel resistance by inhibiting MAPK signaling and increasing paclitaxel accumulation in breast cancer cellsApoptosis induction by MEK inhibition in human lung cancer cells is mediated by BimBRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies.Rnd3 regulation of the actin cytoskeleton promotes melanoma migration and invasive outgrowth in three dimensionsIn vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinaseTargeted therapy in melanoma.Secretory leukocyte protease inhibitor antagonizes paclitaxel in ovarian cancer cellsModulation of matrix elasticity with PEG hydrogels to study melanoma drug responsiveness.From basic research to clinical development of MEK1/2 inhibitors for cancer therapy.High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886)Blockade of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase and murine double minute synergistically induces Apoptosis in acute myeloid leukemia via BH3-only proteins Puma and Bim.Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program.MicroRNA-340 as a modulator of RAS-RAF-MAPK signaling in melanoma.Resistance to chemotherapy and molecularly targeted therapies: rationale for combination therapy in malignant melanomaNovel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and ImmunotherapyPharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice.Enhancement of 5-fluorouracil-induced in vitro and in vivo radiosensitization with MEK inhibition.Therapeutic options in cutaneous melanoma: latest developments.Functional and prognostic relevance of the homeobox protein MSX2 in malignant melanomaA phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumorsBRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and ResistanceRas/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells.The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategiesThe current state of targeted therapy in melanoma: this time it's personalMEK-ERK pathway modulation ameliorates pulmonary fibrosis associated with epidermal growth factor receptor activationTargeting drivers of melanoma with synthetic small molecules and phytochemicals.Targeting the MAPK-RAS-RAF signaling pathway in cancer therapyMEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms.EphA2 as a promoter of melanoma tumorigenicityEffect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma.
P2860
Q21132689-4DBD60D2-5EAB-4B4F-B772-9E35BC7F2EBAQ21133611-CC950F43-82A9-460C-9008-009E44B87642Q24618486-4B6317D6-9452-4467-94A8-E2385F165D71Q26747247-08FF37F3-A6E3-4079-9099-BBC5569FA0A0Q27851426-259ECB7D-0C3B-4F91-AD32-E1781DBF83C8Q28541630-E6898C20-1929-43CD-8959-CA0139409753Q28749134-4E9CE41F-71DC-4864-ADE6-D71649018390Q30458424-F5CCCD41-C7F6-4037-B458-43A22BB03FFAQ30486572-C52B3D15-68DE-4419-9AFD-98DEF76DDF99Q33557673-7E9059A5-F724-4D60-8668-DADB7D3931FFQ33573107-C4CDA561-C883-41D5-AB9E-39AAA90A107FQ33596742-7A1DE7EF-68EA-4CAC-8F71-0C6CD7A1DA49Q33606461-26F0AAEA-BB67-43A0-89F3-C36DFDF839D8Q33698374-5C72B6BB-FD20-4541-8F43-4FEAE190F071Q33717222-1B191233-FC34-42F3-BFD5-5A0360E5A3D8Q33732534-00A9CF2E-C20D-4995-AF1B-C76809942A74Q33906093-DB02E22D-96C8-4457-AA45-ADE856AC1AEBQ33989444-BE1C2CC1-2436-4B92-B3CD-0326EFAB628CQ34307356-4321C8F8-ED50-42F3-93A0-E86BFC6BC1F2Q34415484-1FA93E2A-5B4F-4794-9F31-5F4EB6AF7768Q34459150-C0DAC3E2-D6E1-4CD1-ACEC-C677F9A6AE5BQ34497045-C8D7206A-E0DB-456F-B1C6-20E507DE6142Q34671658-6A24603B-FBAD-4BD2-BD4F-587AE2518763Q35096292-960985C0-3965-4663-B260-D91CC82D8E27Q35146186-5830F564-4F50-46CF-8C67-489C9D2F7168Q35205295-62789F18-D6AC-486E-A35F-8A9E6C0F3CB8Q35208042-DEC2E3ED-4006-4920-92B9-46AC0D9A1887Q35563528-685AE40D-50B6-4603-8261-75A8C7A86E42Q35607456-A77C647F-C09F-460A-A0BD-CC8B81A66BACQ35679353-1F9FE519-10AB-460F-B945-39D54049B8B9Q35692123-B15A4F94-687C-4CC3-B935-D51D221CE6EFQ35835097-30C3B90A-00BB-4A6C-99E8-F1299C915192Q35859282-B60409FA-8E7A-4458-AB71-CE8A607E5645Q35878248-8CDBF298-BD04-491A-83EF-89C3682285C0Q35889180-293F5896-6E76-4073-AB49-F9E6340986CDQ36141097-0D503F4A-29BB-467E-A99E-5A6E39BB70E5Q36278239-78FE5700-1F5A-4471-ABE0-8D4668176ED2Q36328021-42BA8815-25F2-4D4F-97A7-259864CAE14FQ36379022-4DA4B681-D57F-416C-B710-1D65F7DD2E4CQ36507554-04E6F698-9DF6-4C0A-B75F-B3B878A8B517
P2860
The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
The mitogen-activated protein/ ...... when combined with docetaxel.
@en
The mitogen-activated protein/ ...... inase kinase inhibitor AZD6244
@nl
type
label
The mitogen-activated protein/ ...... when combined with docetaxel.
@en
The mitogen-activated protein/ ...... inase kinase inhibitor AZD6244
@nl
prefLabel
The mitogen-activated protein/ ...... when combined with docetaxel.
@en
The mitogen-activated protein/ ...... inase kinase inhibitor AZD6244
@nl
P2093
P50
P1476
The mitogen-activated protein/ ...... when combined with docetaxel.
@en
P2093
C Angelica Medina
Katrin Sproesser
Nikolas K Haass
Rooha Contractor
Thiennga K Nguyen
P304
P356
10.1158/1078-0432.CCR-07-1440
P407
P577
2008-01-01T00:00:00Z